8 results
10-Q
2022 Q1
HLVX
HilleVax Inc
8 Jun 22
Quarterly report
4:25pm
to rely, on third parties for the manufacture of HIL-214, placebo and related raw
materials for clinical development, as well as for commercial … , our third-party manufacturers may rely on single source suppliers for certain of the raw materials for our preclinical and clinical product supplies
424B4
HLVX
HilleVax Inc
29 Apr 22
Prospectus supplement with pricing info
4:02pm
materials for our preclinical and clinical product supplies. If current or future suppliers are delayed or unable to supply sufficient raw materials … sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.
Whether or not we obtain FDA approval
S-1/A
HLVX
HilleVax Inc
18 Apr 22
IPO registration (amended)
6:08am
for the manufacture of HIL-214, placebo and related raw materials for clinical development, as well as for commercial manufacture if HIL-214 or any future vaccine … on single source suppliers for certain of the raw materials for our preclinical and clinical product supplies. If current or future suppliers
S-1
ftuh235uizt ipweb
6 Apr 22
IPO registration
4:21pm
DRS/A
3l5nmqfq3336dnow
23 Nov 21
Draft registration statement (amended)
12:00am
DRS
rtcslz9bem9io9a8xh
19 Oct 21
Draft registration statement
12:00am
- Prev
- 1
- Next